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Summary: Some factors affecting results of digoxin determinations using one commercially available radioimmunoassay
kit are described and discussed.
Serum of pregnant women, cord blood, amniotic fluid and serum of patients taking spironolactone may show
erroneously high digoxin activity due to lack of specificity of the antiserum.
Cross-reaction with digitoxin was found to vary substantially with antibody-lot.
Haemaccel (5 g/1) in the sample leads to too low results. When ethanol (100 g/1) is present results are too high.
The need for testing the specifity of eveiy new lot of antiserum before use is stressed.
Einen käuflichen Radioimmunoassay fur Digoxin mit tritiiertem Digoxin beeinflussende Faktoren
Zusammenfassung: Es werden einige Faktoren, die die Ergebnisse von Digoxin-Bestimmungen mit einen käuflichen
Radioimmunoassay-Besteck beeinflussen, beschrieben und diskutiert.
Aufgrund mangelnder Spezifität des Antiserums können Serum Schwangerer, Nabelschnurblut, Fruchtwasser und
Serum von Patienten, die Spironolacton einnehmen, fälschlich zu hohe Digoxinwerte zeigen.
Die Kreuzreaktion mit Digitoxin variierte mit der Antikörper-Charge.
Haemaccel (5 g/l) in der Probe führt zu zu niedrigen Ergebnissen. In Gegenwart von Ethanol (100 g/l) sind die Ergeb-
nisse zu hoch. Die Notwendigkeit, die Spezifität jeder neuen Antiserum-Charge vor Gebrauch zu testen, wird betont.
Introduction above mentioned factors, we investigated the specificity
of different batches of antiserum to digoxin, and to
The radioimmunoassay of digoxin in serum and plasma digitoxin and spironolactone. Moreover, measurements in
is now a fairly common laboratory procedure. The biological fluids during pregnancy revealed interferences
method and its clinical relevance have been extensively ^^ & 8 batches of antiserum which also showed a
reported in the literature (1-4), Since the report of y^ degree of cross reaction with these drugs. In
the generation of a specific antibody by Butler (5) and addition, false digoxin radioimmunoassay results also
the introduction of a radioimmunoassay procedure by resulted from the presence of ethanol or a plasma expand-
Smith (6) andJEvered (7)> a number of investigators have er jn ̂  assay tube,
reported various factors affecting the results of this
assay. Some of the most important factors are:
quenching (8), radioactive contamination of patient's Materials and Methods
serum (9), chemiluminescence of serum (10), lack of
specificity of the antibody used (11), low intrinsic Chemicals
association constant of the antibody-antigen complex Lanoxitest-ß kit (Wellcome Reagents Ltd Beckenham U.K.),
,,,_ , ff . - 1U . A. . ·. /i'o\ containing antibody, standard digoxin solution, tritiated(12), and effects of albumin on this complex (13). digoxinj horse serum> buffe, (phosphate-albumine buffer
pH 7.40), and albumin coated activated charcoal.
In pur laboratories the digoxin radioimmunoassay has Crystalline digitoxin (Ned. Ph. VII, Nogepha, Aikmaar, The
now been in use for about four years. With regard to the Netherlands).
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Crystalline spironolactone (Searle G. D. & Co., Chicago 111.
60680).
Haemaccel (Farbwerke Hoechst A.G., Abt. Behring Pr parate,
Frankfurt a. M., Germany).
Macrodex and Rheomacrodex (Poviet Produkten B. V., Amster-
dam, The Netherlands).
Scintillation liquid was either Instagel (Cat. no. 6002174
Packard Instrument Co., Inc., Downers Grove, 111. 60515) or
a toluene (1 liter)-Titron-X-100 (0.5 liter)-PPO (5 g)-POPOP
(0.05 g) mixture.
Procedures
Digoxin radioimmunoassay is performed according to the
supplier's instructions, and with the modifications reported
earlier from our laboratories (11).
Solutions of digoxin, spironolactone, digitoxin, Haemaccel,
Rheomacrodex and Macrodex are prepared in the buffer
supplied with the test kit, and assayed in the presence of horse
serum to compensate for differences in standards and samples.
As a measure of the intrinsic association constant of the antigen-
antibody complex, the residual radioactivity after 30 minutes
adsorption to activated charcoal is measured in the super-
natant after centrifugation, and expressed in percentage of the
activity after one minute adsorption.
For extraction, 10 ml methylene chloride is added to a 2 ml
. sample. After mixing thoroughly but gently for 15 minutes, the
tubes are centrifuged, the upper layers removed, and 6 ml of the
methylene chloride fraction evaporated to dryness. The residue
is dissolved in 0.1 ml ethanol and made up to 1.0 ml with
buffer.
Beta counting is conducted in either the Tricarb Model 2425
(Packard) or in the Mark II (Nuclear Chicago Corp., Des Plaines,
111. 60018) liquid scintillation counter. Quench correction was
made by the external standard ratio method.
Plasma or serum samples from patients on digoxin were drawn at
least six hours after the last dose. Pools of maternal- and cord
blood-serum and of amniotic fluid were obtained at delivery
from nine women, who were not taking any medication.
Results and Discussion
After we started to determine plasma digoxin routinely
in 1971, we were confronted with several types of inter-
ference with this assay.
Table 1 summarizes an in vitro comparison of the
specificity of different antibody batches. The measure-
ments were performed at least in duplicate in two
laboratories. The given values are means of these
measurements with a standard deviation of 0.2 μ§/1. A
control digoxin serum containing 3.0 μ§/1 (column e)
was measured throughout to ensure the validity of the
results.
Spironolactone
In some patients without clinical signs of digoxin
intoxication high plasma digoxin concentrations, sugges-
ting toxicity, were measured. Some of these patients
were medicated with both digoxin and spiroriolactone.
So we studied another group of patients using spirono-
lactone only. Apparent digoxin concentrations of
0.3—1.7 μg/l were found in seven patients receiving
daily doses of spironolactone of either 100 or 150 mg
(16). In table la the apparent digoxin concentrations,
measured with different antibody charges at fixed
spironolactone concentrations added in vitro are presented.
Figure 1 shows the response of two antibody charges to
increasing concentrations of spironolactone. Using anti-
body of charge no. K3650, an increasing cross reaction
with spironolactone was found, but no significant
effect was observed when antibody K7200 was used. So
it is clear that the interference by spironolactone
depends on the antibody charge used.
From .the active metabolites of spironolactone we could
study only the effect of caiirenoate. This showed no
cross reaction, probably because of opening of the
γ-lactone ring. (See fig. 2). Unfortunately canfenon, the
other metabolite which has a γ-lactone ring, was not
available.
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Figures given are means of 4 to 8 determinations. Standard deviation: 0.
Figures between parentheses are not significant (p > 0.05)
a: lot number unknown: delivered January 1972
b: spironolactone concentration: 250 Mg/1
c: spironolactone concentration: 2000 /ig/1
d: digitoxin concentration: 40 Mg/1
e: cpmi = after 1 minute time of adsorption to charcoal
= after 30 minutes time of adsorption to charcoal
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Fig. 1. Response to spironolactone of two different antibody
charges used in the radioimmunoassay of digoxin.
• · antiserum lot number-K3650
• — · antiserum lot number K7200
Each point represents the mean of four determinations.
The standard deviation was 0.2 Mg/1.
Digoxin
Spironolactone
Fig. 2. Formulas of digoxin and spironolactone. The active
metabolites of spironolactone are formed by splitting
off of the thiqlacetyl group - canrenon, which is in
equilibrium with canrenoate by opening of the -y-lactone
ring.
In an article of Ravel (18) negligible interference by
spironolactone and prednisone is described. Unfortunate^·
ly he did riot mention the lot numbers of the kits he
used, as his results using the Corning and Kallestädt kit
suggest an antibpdy^dependent interference.
Moreover the dose of spironolactone administrated to
the patients of Zeegers (11) was twice that received by
the patients of Ravel
Digitoxin
The manual of the digoxin radioimmunoassay kit states
that this kit can also be used for the estimation of serum
digitoxin: "digitoxin will crossreact in the assay with
about l/10th of the activity of digoxin on a weight
basis". The first kits we used gave satisfactory results for
the assay of digitoxin. However, when new lots were
delivered, the cross reaction of digitoxin was reduced to
about l/20th, and even l/40th of the activity of digoxin.
Because of this lack of sensitivity to digitoxin we had to
reject the kit for the digitoxin assay. To illustrate the
effect of the quality of the antibody Table 1 b presents
the apparent digoxin concentration in a serum containing
20 /ig/1 digitoxin, measured with different charges of
antibody. One can conclude that a varying degree of
cross reaction is found with different antibody charges.
Therefore, when both substances are administered to
patients, no uniform correction factor for the interference
of digitoxin in the radioimmunoassay of digoxin can be
applied as suggested by Kuno-Sakai (14). In the paper of
Kubasik et al. (15), who compared five commercially
available kits for the radioimmunoassay of digoxin, two
different lot numbered kits of each supplier, showed
only minor variations. In our study, the antibody of the
low numbered lots shows much more cross reaction than
the high numbered.
Pregnancy (maternal blood, amniotic fluid, and cord
blood)
In an attempt to study the placental passage of digoxin
we found apparently toxic digoxin concentrations up to
6.2 Mg/1 in amniotic fluid and cord blood during
pregnancy in five women taking digoxin. Maternal serum
digoxin concentrations were in the normal therapeutic
range. None of the babies showed any sign of digitalis
intoxication. The result of the assays suggested accumu-
lation of digoxin in amniotic fluid and cord blood.
However, values for digoxin in maternal plasma ranged
from 0.2 to 0.7 /zg/1 in nine pregnant patients receiving
no digoxin. Corresponding values for digoxin in amniotic
fluid and cord blood plasma ranged from 1.35 to 2.5
Mg/1 (see also Jambroes et al. (16)). This interference was
also found to depend on the antibody charge used. For
this study pooled samples of maternal and fetal plasma,
and amniotic fluid from the same pregnant women, not
on digitalis, were assayed for apparent digoxin activity.
The results are presented in table Ic, showing again an
antibody charge-dependent interference with the radio-
immunoassay of digoxin.
A study on transplacental passage of digoxin, using a
reliable antibody, will be published elsewhere.
Influence of the association constant of the antibody
Zeegers et al. (11) observed that variations in the con-
tact-time of the antigen-antibody system with charcoal
(to remove unbound digoxin) can greatly influence the
results of the tests. They concluded that this period
should be meticulously standardized. Smith & Haber (12)
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(12) ascribed this contact-time effect to differences in
the intrinsic association constant of the antibody-antigen
complex. To investigate this phenomenon we measured
the residual antibody-bound [3H]digoxin activity after
30 minutes contact with charcoal and expressed it as the
percentage of the activity after 1 minute contact-time,
using all the available batches of antibody. The apparent
rates of dissociation of the antibody-antigen complex
for the different batches are listed in table Id, showing
a variation from 65 up to 88 percent. Zero values
(CPM0-Blank
Total CPM-Blank)
were between 50 and 60%. Kuno-Sakai et al. (17) who
also studied the effect of variations in contact time to
charcoal stated that the magnitude of this effect varies
with the manufacturer. Our results however emphasize
differences between antibody charges from one manu-
facturer.
Smith & Haber related a poor intrinsic association
constant of the antibody-antigen complex with a lack of
specificity of the antibody. From the results in Table
la-d, especially with antibody charges no. χ, Κ8184,
and K9100, one can see that their conclusion does not
hold for all batches; from the results with those that we
studied, it can be concluded that cross reaction with one
interfering substance is concomittant with interference
by other crossreactants.
With reference to the problems described so far, we
would like to quote Th. W. Smith & E. Haber in Pharma-
cological Reviews 1973 (page 224). "Unfortunately,
commercial suppliers of radioimmunoassay material
have in general supplied the purchaser with inadequate
data characterizing the antibodies supplied. The respon-
sibility for quality control therefore rests with the user.
Minimum documentation of the suitability of a given
antibody for radioimmunoassay use would require
hapten inhibition studies to define specificity, and
charcoal contact time studies to define the range of
contact times which could be used without introducing
an unacceptable degree of error". In this study we have
followed these suggestions for radioimmunoassay kits
obtained from one manufacturer. Differences between
several commercially available digoxin radioimmunoassay
kits are extensively reported in literature (15).
Haemaccel*)
In a study on digoxin pharmacokinetics in patients
during cardiopulmonary bypass we sometimes found
very low or even apparently negative plasma digoxin con-
centrations (tab. 2). No corrections were made for back-
ground counts in these samples. As a control the pump
Tab. 2. Digoxin concentration in untreated vs. extracted blood











































) The effects of Haemaccel and ethanol were studied with
antibody charge K9100.
A recently delivered lot (K0061) gave similar results.
priming was measured, which gave an apparently negative
digoxin level. As no radioactive contamination could be
detected all constituents of the pump priming were
tested. From these, Haemaccel turned out to interfere
negatively with the radioimmunoassay of digoxin. We
decided to study this effect more comprehensively.
The "in vitro" influence of Haemaccel is illustrated in
figure 3, representing a normal calibration curve and a
calibration curve with addition of Haemaccel to the
standards at a concentration of 5 g/1. From figure 3 one
may see that the curves a and b do not run parallel. This
means that there is no constant effect of Haemaccel in the
digoxin concentration range we studied. When antibody
is omitted (i.e. the blank), more radioactivity is measured
in the presence of Haemaccel than in its absence. Less
[3H]digoxin is adsorbed to charcoal, depending on the
Haemaccel concentration. When blanks were measured
at different known unlabelled digoxin concentrations,
no decrease of this effect could be detected. In other
words, the influence of Haemaccel on the binding of
digoxin to charcoal is independent of the digoxin con-
centration. There are no signs of interference in beta
counting caused by quenching or chemiluminescence.
So the effect must be attributed to interference with the
adsorption to charcoal and possibly also with the
formation of the antibody-antigen complex.
Though a combined administration of digoxin and
Haemaccel is very rare, under these circumstances the
observed interference may give rise to a misleading
interpretation of serum digoxin assay results, especially
at high digoxin levels. At zero digoxin concentrations a
decrease of 0.1 μg/l is found; at a known digoxin value
of 3.0 μg/l, the measured value may be decreased by as
much as 1.0 μg/l. This interference was not observed
with two other plasma substitutes, Macrodex and
Rheomacroeex.
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Fig. 3. Effect of Haemaccel (5 g/1) on the radioimmunoassay
of digoxin.
curve a: * *: normal calibration curve
curve b: ο ο: calibration curve in the presence of
Haemaccel
curve c: · — ·: as curve a after extraction fNo correction
I was made
•s for final
curve d: Δ—^-Δ: as curve b after extraction volume differ-
[ences (see text)
Each point represents the mean of four determinations.
The coefficient of variation of cpm's was < 5%. Significance
of difference between the points of curve a and b: ρ < 0.02
at 0 Mg/1 digoxin and ρ < 0.01 at all other concentrations.
Curve c and d did not differ significantly.
To avoid the problems caused by Haemaccel, digoxin can
be extracted from the samples with methylene chloride;
as illustrated in figure 3, curves c and d, normal and
Haemaccel-containing standards then give the same values*
For a clearer presentation rio correction was made for the
fact that the final volume of 1.0 ml for extractions really
represents 1.2 ml of sample.
It should be noticed that this extraction is not a standard
procedure in the digoxin radioimmunoassay, and that the
presence of Haemaccel in serum is not s easily recognized
as haemolysis, jaundice or radioactive contamination.
Provided that Haemaccel does not interfere with the
antibody-antigen binding, the observed phenomenon
should be a stimulus to use separation techniques in
which the antibody-antigen complex is removed, for
example, by imm n -precipitation or by solid phase
antibody.
and without Haemaccel, we concluded that ethanol
might have an effect on the assay (see curves a and c in
Fig. 3). To study this influence we replaced the normal
buffer with buffer containing a quantity of ethanol
equivalent to or twice that used after extraction.
The result of this addition is presented in figure 4. It is
clear that ethanol causes a small positive error in the
assay. Ten percent ethanol in a sample causes about
0.1—0.2 jug/1 increase in the observed digoxin concen-
tration (p < 0.05).
In patients undergoing cardiopulmonary bypass low
plasma digoxin concentrations are to be expected, since
digoxin administration is usually discontinued 48 hours
prior to surgery. The small positive effect of ethanol may
therefore lead to errors of up to 100% in the observed
tissue: plasma ratio of digoxin. Moreover this experiment
shows that the standards for the assay should not contain
ethanol. Variations in results between commercially







Fig. 4. Effect of ethanol on the radioimmunoassay of digoxin.
curve a: * *: normal calibration curve
curve b: Δ—-Δ: calibration curve with ethanol (1/9 by vol.)
curve c: ο ο: calibration curve with ethanol (1/4 by vol.)
Each point represents the mean of four determinations. The
coefficient of variation of cpm's was < 5 %. Significance of
difference between the points of:
Ethanol1)
From the differences between extracted and unextracted










of all points: 40 cpm
p < 0.05
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